Almotriptan
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Almotriptan: 5-HT1B/1D receptor agonist → atrophoderma vermiculata
One-Sentence Summary
Almotriptan is a serotonin 5-HT1B/1D receptor agonist (triptan class) marketed in India as oral tablets. The TxGNN model predicts it may be relevant to atrophoderma vermiculata, a rare follicular atrophic skin disorder, but no clinical trials and no publications currently support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | atrophoderma vermiculata |
| TxGNN Prediction Score | 0.9977 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (6 of 6) – CDSCO approval status is not included in this data |
| Number of Listed Products | 6 (valid: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Almotriptan belongs to the triptan class, which acts as a 5-HT1B/1D receptor agonist and causes vasoconstriction of cranial blood vessels.
For atrophoderma vermiculata, no credible mechanistic link was identified. It is a rare atrophic disorder of hair follicles affecting the cheeks, and serotonergic vasoconstrictive action has no known role in its pathology. The high TxGNN score is therefore best treated as a model output without biological or clinical backing, possibly driven by shared genetic or phenotype associations in the underlying network. It should not be read as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 1265 | Almotan 6.25 Tablet | Strip of 4 tablets | Not recorded |
| 17044 | Almigra 6.25mg Tablet | Strip of 4 tablets | Not recorded |
| 5657 | Almogril 12.5mg Tablet | Strip of 10 tablets | Not recorded |
| 9291 | Amlotan 6.25mg Tablet | Strip of 4 tablets | Not recorded |
| 8436 | Almogril 6.25mg Tablet | Strip of 10 tablets | Not recorded |
All six registered single-ingredient licences are valid; the table lists the first five.
Safety Considerations
- Drug Interactions: 56 interactions were recorded. Major-level interactions include the serotonergic or 5-HT-related agents dexfenfluramine, fenfluramine, lorcaserin and sibutramine, and the 5-HT3 antagonists dolasetron, granisetron, ondansetron and palonosetron. Moderate-level interactions include aprepitant, clarithromycin and morphine (including liposomal).
- Conditions flagged as cautions for this drug class: hypertension, coronary artery disease, myocardial infarction, stroke and cerebrovascular disorders, peripheral vascular disease, Raynaud disease, Prinzmetal angina, liver disease, serotonin syndrome and hemiplegic migraine, among others. These are relationships recorded in the data compiled for this report, not label text, and should be checked against the package insert.
Package insert warnings and contraindications were not available and should be reviewed directly.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a high model score (0.9977). There are no trials or publications on this disease, no plausible mechanism links a 5-HT1B/1D agonist to atrophoderma vermiculata, and the cardiovascular cautions of the drug class add risk. Evidence level is L5.
To proceed, the following is needed:
- A credible mechanistic hypothesis connecting 5-HT1B/1D agonism to follicular atrophic skin pathology
- Preclinical or case-level evidence directly addressing atrophoderma vermiculata
- Package insert warnings and contraindications from the India regulatory records
- Detailed mechanism-of-action data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.